Menu Search
Equities

NervGen Pharma Corp

NGEN:CVE

NervGen Pharma Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CAD)2.69
  • Today's Change0.16 / 6.32%
  • Shares traded42.54k
  • 1 Year change+37.95%
  • Beta1.3766
Data delayed at least 15 minutes, as of Nov 22 2024 20:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in CADView more

In 2023, cash reserves at NervGen Pharma Corp fell by 10.79m. Cash Flow from Financing totalled 766.29k or -- of revenues. In addition the company used 11.30m for operations while cash used for investing totalled 138.85k.
Cash flow per share-0.368
Price/Cash flow per share--
Book value per share0.1308
Tangible book value per share0.124
More ▼

Balance sheet in CADView more

NervGen Pharma Corp uses little debt in its capital structure as supported by a debt to capital ratio of 1.39%.
Current ratio1.66
Quick ratio--
Total debt/total equity0.0141
Total debt/total capital0.0139
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.